Connect with us

Business

Pfizer trial participant Sen. Steve Daines urges trust

Published

on

Republican Sen. Steve Daines of Montana on Friday urged Americans to have confidence in the coronavirus vaccine from Pfizer and BioNTech, relying on his experience as a participant in the companies’ phase three clinical trial.

The U.S. pharmaceutical giant and German biotech firm said earlier Friday they intended to apply for emergency use authorization from the U.S. Food and Drug Administration, making them the first companies to do so for a Covid-19 vaccine. Final data released this week showed the vaccine was 95% effective in preventing the disease. The FDA’s review process is expected to take a few weeks.

“This is great news for the American people. This is how we bring an end to this pandemic,” Daines said on “The Exchange.” “The reason my wife and I participated in it is we want to help build confidence and trust in these vaccines.”

Daines said he did not experience major side effects after he received his first inoculation in the trial in late August. Pfizer’s vaccine requires two doses. While participants in double-blind studies are not told whether they receive the vaccine or a placebo, Daines said he has reason to believe he actually got the experimental candidate.

“It reminded me of getting the flu shot. It was virtually painless, the vaccine itself. I had a little bit of a sore arm for a couple days, and then I had slight chills the day after that lasted about a few hours. They resolved, and I felt completely fine the next day,” said Daines, who won reelection earlier this month. “That was probably an indicator that I had the vaccine.”

Daines also said he later tested positive for Covid-19 antibodies, which can help build immunity and prevent reinfection. Pfizer and BioNTech’s vaccine produces neutralizing antibodies.

Daines is the second Republican senator this week to announce his participation in vaccine trials. On Tuesday, Sen. Rob Portman of Ohio told CNBC he had enrolled in Johnson & Johnson‘s phase three trial. The men shared similar motivations for signing up.

“It’s one thing to have the vaccines, which I think will be ready by the end of this year, so really in just a month and a half, but we’ve got to be sure that people are willing to be vaccinated,” Portman said. “So the reason I participated in this trial was because I think the vaccines are so important.”

The news of Pfizer and BioNTech’s FDA submission arrives at a critical moment in the U.S. coronavirus pandemic. New daily infections have risen to record levels and so have hospitalizations for Covid-19 patients. On Thursday, deaths reached a level not seen since early May.

Multiple federal agencies have begun telling workers they could be immunized with the Covid-19 vaccine from Pfizer and BioNtech — or Moderna, which is nearing an FDA application — in as little as eight weeks, CNBC reported Friday, citing a person with knowledge of the plans.

Any coronavirus vaccine approved would be limited in quantity at first. Health-care workers, along with elderly people and those who have underlying health conditions, are likely to receive the vaccine initially. As soon as the FDA issues approval, “within 24 hours, the vaccines will be in the immunization sites and people will be immunized,” Operation Warp Speed advisor Dr. Moncef Slaoui told CNBC on Friday.


Source link

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Business

Here are the best deals (and what not to buy)

Published

on

By

Continue Reading

Business

Customers will see only benefits

Published

on

By

David McInerney, CEO, FreshDirect

Source: CNBC

FreshDirect customers have nothing to fear after the company was bought by the Dutch owner of Stop & Shop and Food Lion, the grocery delivery service’s CEO said Tuesday.

Ahold Delhaize and Centerbridge Partners, a private equity firm, announced Wednesday that they would be buying FreshDirect. Financial terms of the deal were not disclosed, but Ahold Delhaize will acquire a majority stake and Centerbridge Partners will have a minority investment of 20%.

“Hopefully the only differences that customers see are the benefits,” FreshDirect CEO David McInerney said on CNBC’s “Squawk Box.”

The Dutch company already has a foothold in U.S. grocery e-commerce through Peapod, which was the first company in the country dedicated to online grocery delivery. But FreshDirect’s specialty is fresh food, which represents about 60% of its total sales, and it has a higher market share than Peapod in the New York tri-state area.

McInerney said that he appreciated how Ahold Delhaize plans to preserve the e-commerce company’s brand. FreshDirect will keep its name and will still independently operate its New York City facility.

“I think combining the knowledge of both companies, we can make it even more competitive and compelling,” Ahold Delhaize CEO Frans Muller said.

Stockpiling during the early days of the coronavirus pandemic made online grocery sales soar, and the trend seems to be sticking. Muller said that the pandemic accelerated Ahold Delhaize’s e-commerce business by several years.

“Being that we’re on top of our game right now … strong double digit-growth, we were naturally attractive, given where the world is in terms of adoption of online food,” McInerney told CNBC’s Becky Quick.

The deal is expected to close in the first quarter of 2021.

Correction: David McInerney is CEO of FreshDirect. An earlier version misspelled his name.


Source link

Continue Reading

Business

Trump administration officials speak on Covid vaccine distribution

Published

on

By

[The stream is slated to start at 11:15 a.m. ET. Please refresh the page if you do not see a player above at that time.]

The departments of Health and Human Services and Defense are holding a joint briefing Tuesday on the Trump administration’s coronavirus vaccine program Operation Warp Speed as states prepare to distribute doses as early as next month.

The briefing comes four days after Pfizer and its partner BioNTech applied for an emergency use authorization from the Food and Drug Administration for their Covid-19 vaccine. The FDA process is expected to take a few weeks, and an advisory committee meeting to review the vaccine has been scheduled for early December.

Pfizer announced on July 22 that the U.S. agreed to buy 100 million doses of its vaccine for up to $1.95 billion. The agreement, which is part of Operation Warp Speed, allows the U.S. to acquire an additional 500 million vaccine doses.

Read CNBC’s live updates to see the latest news on the Covid -19 outbreak.


Source link

Continue Reading

Breaking News

Shares